Psilocybin as an emerging anxiolytic: mechanisms

Psilocybin as an emerging anxiolytic: mechanisms, evidence, and open questions. Anxiety disorders are among the most prevalent psychiatric conditions worldwide, yet the pharmacological landscape has changed very little in recent decades. Selective serotonin reuptake inhibitors remain first-line treatments.

Psilocybin, a naturally occurring indoleamine prodrug rapidly dephosphorylated in vivo to the active metabolite psilocin, has emerged as a mechanistically distinct anxiolytic candidate with notable convergence across preclinical, neuroimaging, and clinical data [ 1 ]. Direct clinical evidence in anxiety disorders remains limited. Two randomized double-blind trials demonstrated that a single high-dose psilocybin session produced large, sustained reductions in anxiety in patients with life-threatening cancer—about 80% maintained clinically significant improvements at 6-month follow-up, with effect sizes exceeding Cohen’s d = 2.0 [ 3, 4 ].

A meta-analysis of six double-blind RCTs ( N = 528) confirmed that acute anxiety adverse events were transient, commonly resolving within 48 hours, while therapeutic anxiolytic effects emerged simultaneously relative to active placebo [ 5 ]. This is a preview of subscription content, access via your institution Access options Access through your institution. More Information Buy this article Purchase on SpringerLink Instant access to the full article PDF.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with qualified healthcare professionals for medical decisions and treatment options.